Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry

被引：0
|
作者：
Yun, Huifeng [1 ]
Curtis, Jeffrey [2 ]
Chen, Lang [1 ]
Clinton, Cassie [1 ]
van Hoogstraten, Hubert [3 ]
Fiore, Stefano [3 ]
Rehberg, Markus [4 ]
Choy, Ernest [5 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Dept Epidemiol, Dept Med, Birmingham, AL USA
[3] Sanofi, Bridgewater, NJ USA
[4] Sanofi, Franfurt, Germany
[5] Cardiff Univ, CREATE Ctr, Cardiff, Wales
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1243
引用
收藏
页码：2568 / 2570
页数：3
相关论文
共 50 条
  • [1] Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
    Curtis, Jeffrey R.
    Yun, Huifeng
    Chen, Lang
    Ford, Stephanie S.
    van Hoogstraten, Hubert
    Fiore, Stefano
    Ford, Kerri
    Praestgaard, Amy
    Rehberg, Markus
    Choy, Ernest
    RHEUMATOLOGY AND THERAPY, 2023, 10 (04) : 1055 - 1072
  • [2] Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
    Jeffrey R. Curtis
    Huifeng Yun
    Lang Chen
    Stephanie S. Ford
    Hubert van Hoogstraten
    Stefano Fiore
    Kerri Ford
    Amy Praestgaard
    Markus Rehberg
    Ernest Choy
    Rheumatology and Therapy, 2023, 10 : 1055 - 1072
  • [3] Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
    Jeffrey R. Curtis
    Huifeng Yun
    Lang Chen
    Stephanie S. Ford
    Hubert van Hoogstraten
    Stefano Fiore
    Kerri Ford
    Amy Praestgaard
    Markus Rehberg
    Ernest Choy
    Rheumatology and Therapy, 2024, 11 (1) : 217 - 217
  • [4] Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
    Rehberg, Markus
    Giegerich, Clemens
    Praestgaard, Amy
    van Hoogstraten, Hubert
    Iglesias-Rodriguez, Melitza
    Curtis, Jeffrey R.
    Gottenberg, Jacques-Eric
    Schwarting, Andreas
    Castaneda, Santos
    Rubbert-Roth, Andrea
    Choy, Ernest H. S.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1661 - 1675
  • [5] Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
    Rehberg, Markus
    Giegerich, Clemens
    Praestgaard, Amy
    van Hoogstraten, Hubert
    Iglesias-Rodriguez, Melitza
    Curtis, Jeffrey R.
    Gottenberg, Jacques-Eric
    Schwarting, Andreas
    Castaneda, Santos
    Roth, Andrea Rubbert
    Choy, Ernest
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
    Markus Rehberg
    Clemens Giegerich
    Amy Praestgaard
    Hubert van Hoogstraten
    Melitza Iglesias-Rodriguez
    Jeffrey R. Curtis
    Jacques-Eric Gottenberg
    Andreas Schwarting
    Santos Castañeda
    Andrea Rubbert-Roth
    Ernest H. S. Choy
    Rheumatology and Therapy, 2021, 8 : 1661 - 1675
  • [7] Disease severity and outcomes among patients with rheumatoid arthritis who receive a newly approved biologic: Real-world US experience with Sarilumab from the ACR RISE registry
    Curtis, Jeffrey R.
    Fiore, Stefano
    Chen, Lang
    Clinton, Cassie
    Yun, Huifeng
    Praestgaard, Amy
    Ford, Kerri
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 645 - 645
  • [8] DISEASE SEVERITY AND OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS WHO RECEIVE A NEWLY APPROVED BIOLOGIC: REAL-WORLD US EXPERIENCE WITH SARILUMAB FROM THE ACR RISE REGISTRY
    Fiore, S.
    Chen, L.
    Clinton, C.
    Yun, H.
    Praestgaard, A.
    Ford, K.
    Curtis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 556 - 557
  • [9] Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
    Fiore, Stefano
    Chen, Lang
    Clinton, Cassie
    Yun, Huifeng
    Praestgaard, Amy
    Ford, Kerri
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [10] Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
    Pappas, Dimitrios A.
    Reed, George W.
    Karki, Chitra
    Griffith, Jenny
    Skup, Martha
    Garg, Vishvas
    Kremer, Joel
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345